Aligos Therapeutics (ALGS) Return on Capital Employed (2020 - 2026)
Aligos Therapeutics (ALGS) reported Return on Capital Employed of 23.86% for Q1 2026, up 7056.0% on a YoY basis from 0.33% in Q1 2025, and down 270.76% quarter-over-quarter from 6.44% in Q4 2025.
Aligos Therapeutics (ALGS) Return on Capital Employed (2020 - 2026) Analysis & Trends
Aligos Therapeutics has reported Return on Capital Employed for 7 years, with the latest figure at 23.86% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 7056.0% year-over-year to 23.86%; the trailing twelve-month figure through Mar 2026 stood at 23.86% (up 7056.0% YoY), and the FY2025 full-year result was 8.63%, up 9146.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 23.86%, down from 6.44% in the prior quarter.
- The five-year high for Return on Capital Employed was 6.44% in Q4 2025, with the low at 154.99% in Q4 2024.
- Historically, Return on Capital Employed has averaged 83.53% across 5 years, with a median of 80.97% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 6201 bps — and 2025, when it surged 14855 bps.
- Aligos Therapeutics' Return on Capital Employed stood at 79.82% in 2022, then slipped by 16 bps to 92.98% in 2023, then plunged by 67 bps to 154.99% in 2024, then surged by 96 bps to 6.44% in 2025, then slumped by 271 bps to 23.86% in 2026.
- The last three Return on Capital Employed figures came in at 23.86% (Q1 2026), 6.44% (Q4 2025), and 86.52% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | -23.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.86% |
| Dec 31, 2025 | -6.44% |
| Sep 30, 2025 | -86.52% |
| Jun 30, 2025 | -64.12% |
| Mar 31, 2025 | -94.43% |
| Dec 31, 2024 | -154.99% |
| Sep 30, 2024 | -121.79% |
| Jun 30, 2024 | -98.67% |
| Mar 31, 2024 | -71.38% |
| Dec 31, 2023 | -92.98% |
| Sep 30, 2023 | -115.35% |
| Jun 30, 2023 | -97.67% |
| Mar 31, 2023 | -80.97% |
| Dec 31, 2022 | -79.82% |
| Sep 30, 2022 | -79.05% |
| Jun 30, 2022 | -77.02% |
| Mar 31, 2022 | -74.98% |
| Dec 31, 2021 | -61.03% |
| Sep 30, 2021 | -61.50% |
| Jun 30, 2021 | -58.59% |